Alnylam Reports Positive Initial Phase 1b Data for Brezosiran
Alnylam reported positive initial Phase 1b results for ALN-HTT02, an investigational RNAi therapy for Huntington’s disease, demonstrating deep and durable huntingtin lowering.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.